Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) Meeting Abstract

  

Authors:	Nowakowski, G. S.; Yoon, D. H.; Joffe, E.; Zinzani, P. L.; Sabatelli, L.; Waltl, E. E.; Alvero, C. G.; Hess, G.; Riedell, P. A.; Kim, K.; Brixner, D.; Salles, G. A.
Abstract Title:	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Meeting Title:	2022 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	16 Suppl.
Meeting Dates:	2022 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-06-01
Language:	English
ACCESSION:	WOS:000863680302021
PROVIDER:	wos
DOI:	10.1200/JCO.2022.40.16_suppl.7560
Notes:	Meeting Abstract: 7560 -- Meeting also held virtually -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201506